Skip to content

Cumberland Pharmaceuticals CPIX Free cash flow margin

Free cash flow margin at other companies

Baxter International logo
Baxter InternationalBAX
3%-2.4pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-76.8%
RFL
Rafael Holdings, Inc.RFL
-2,064.1%
Opko Health logo
Opko HealthOPK
-30%+0.1pp
Organon logo
OrganonOGN
11.1%-1.3pp
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-30.3%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's free cash flow margin?
Cumberland Pharmaceuticals (CPIX) reported free cash flow margin of 3.3% in Q1 2026.
What is the long-term trend for Cumberland Pharmaceuticals's free cash flow margin?
Over 4 years (2020 to 2025), Cumberland Pharmaceuticals's free cash flow margin has grown at a -6.3% compound annual growth rate (CAGR), from 14.1% to 10.9%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.